Human placental extract effectively and safely improves melasma, ulcers, and alopecia areata.
August 2020 in “European Journal of Dermatology” Dutasteride for hair loss can cause skin reactions like itchy red plaques.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
December 2025 in “Orvosi Hetilap” Baricitinib is effective and safe for treating alopecia areata.
January 2024 in “Journal of Clinical Rheumatology and Immunology” Monitor for early signs of myelosuppression, like hair loss, in patients on azathioprine to manage side effects.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
49 citations
,
January 1994 in “The Journal of Steroid Biochemistry and Molecular Biology” RU 58841 may treat acne, hair loss, and excessive hair growth.
6 citations
,
February 2019 in “JAAD case reports” Acitretin helped improve hand mobility and skin condition in a patient.
November 2022 in “Indian Journal of Dermatology” Azole antifungals can cause skin reactions like EAC, requiring careful management.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
51 citations
,
July 2003 in “Annals of the Rheumatic Diseases” Co-trimoxazole may help treat autoimmune diseases.
July 2026 in “Dermatology and Therapy” Baricitinib and ritlecitinib are both effective and safe for treating severe alopecia areata.
5 citations
,
November 2015 in “Journal of Enzyme Inhibition and Medicinal Chemistry” Certain derivatives are more effective 5α-reductase type 2 inhibitors than finasteride.
10 citations
,
November 2014 in “Sexual medicine reviews” Effective, well-tolerated, and affordable treatments are needed for recurrent ischemic priapism.
June 2026 in “Drugs & Therapy Perspectives” Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients.
July 2025 in “Journal of Investigative Dermatology” Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.
114 citations
,
December 1951 in “Archives of Dermatology” Aminopterin strongly suppresses epithelial tissues and can treat certain skin conditions but has significant side effects.
June 2023 in “Value in Health” Alopecia areata treatments often cause headaches and infections, highlighting the need for safer options.
June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
23 citations
,
October 2005 in “Journal of The American Academy of Dermatology” Two transplant patients on cyclosporine unexpectedly developed hair loss.
November 2025 in “The Journal of Immunology” The S1PR 1&4 modulator may effectively treat alopecia areata by reducing hair loss and immune cell activity.
1 citations
,
November 2018 in “Therapeutic Delivery” New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
February 2017 in “Medicina cutánea ibero-latino-americana” An 8-year-old boy with hair loss had hair regrowth and responded well to clobetasol propionate treatment.
Azathioprine can cause severe hair loss and low white blood cell count in lupus patients.
August 2021 in “Journal of the American Academy of Dermatology” Oral baricitinib is effective and safe for treating alopecia areata.
5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
21 citations
,
October 2023 in “Journal of Dermatological Treatment” Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.
June 2023 in “BMC Pharmacology and Toxicology” The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.